Probiotic strain selection by condition: a practical guide

The most important principle in probiotic supplementation is that effects are strain-specific, not species-specific. Lactobacillus rhamnosus GG is not equivalent to Lactobacillus rhamnosus GR-1, and a generic "Lactobacillus" capsule is not interchangeable with a trial-validated strain at a trial-validated dose. The World Gastroenterology Organisation guidelines and ISAPP consensus statements have repeatedly emphasized this distinction. Here is what the trial record actually supports.

IBS: which strains have positive trials

Bifidobacterium longum 35624 (formerly Bifidobacterium infantis 35624) has the strongest single-strain RCT base for IBS, with at least three randomized placebo-controlled trials showing improvements in composite symptom scores at 1 billion CFU/day for 4-8 weeks [1]. Lactobacillus plantarum 299v has supporting trials in IBS-D specifically, and the multi-strain VSL#3/Visbiome formulation has trials in pouchitis and IBS with bloating. Generic Lactobacillus acidophilus alone has not produced reliable IBS benefit and should not be substituted for trial-validated strains.

Antibiotic-associated diarrhea

The Cochrane and AGA reviews converge on three options with reliable preventive evidence. Saccharomyces boulardii CNCM I-745 (5 billion CFU twice daily) reduces antibiotic-associated diarrhea by approximately 50% in pooled adult and pediatric trials [2]. Lactobacillus rhamnosus GG (10-20 billion CFU/day) has similar effect size in pediatric trials but is less effective in adult Clostridioides difficile prevention than S. boulardii [3]. A combination of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R has trial evidence specifically for hospital-onset C. difficile prevention.

Infant colic

Lactobacillus reuteri DSM 17938 at 100 million CFU/day reduces crying time by 25-50 minutes per day in breastfed infants with colic, based on six placebo-controlled trials [4]. The effect is consistent for breastfed but not formula-fed infants. Other Lactobacillus or Bifidobacterium strains, and probiotic blends, have not produced equivalent benefit and are not endorsed by the European Society for Paediatric Gastroenterology.

Inflammatory bowel disease

For ulcerative colitis, VSL#3/Visbiome (a multi-strain product containing four Lactobacillus, three Bifidobacterium, and one Streptococcus) has trial evidence for inducing and maintaining remission in mild-to-moderate disease and for treating pouchitis [5]. Escherichia coli Nissle 1917 has European data showing non-inferiority to mesalamine for maintenance of remission. No single-strain Lactobacillus product has equivalent IBD evidence.

Vaginal and urinary tract health

Lactobacillus rhamnosus GR-1 plus Lactobacillus reuteri RC-14 taken orally has trial evidence for restoring vaginal microbiota after bacterial vaginosis treatment and for reducing recurrence of urinary tract infections in women, though effect sizes are modest [6]. Other Lactobacillus combinations marketed for "women's health" generally lack strain-specific trial support.

Common errors in interpretation

First, dose matters. Trial-validated CFU counts range from 1 billion (B. longum 35624) to 900 billion (VSL#3 high-dose), and a product containing 1 billion CFU of the same strain used at 100 billion in trials is not equivalent. Second, multi-strain products are not automatically better. The ISAPP consensus is that combination products should be tested as the specific combination; component evidence does not transfer [7]. Third, expiration and storage matter; many probiotics lose viability at room temperature and the CFU count on the label refers to date of manufacture, not date of expiry.

Bottom line

Probiotic selection should match the specific strain and dose to the indication: B. longum 35624 for IBS, S. boulardii CNCM I-745 or L. rhamnosus GG for antibiotic-associated diarrhea, L. reuteri DSM 17938 for breastfed-infant colic, VSL#3/Visbiome or E. coli Nissle 1917 for ulcerative colitis. Generic Lactobacillus blends without strain identifiers do not carry over evidence from the validated products.